Mouse study links weight regain after GLP-1 use to lasting change in fat cells

A study in mice describes a lasting change in fat tissue that keeps a hunger signal turned up after weight loss, and its authors say it may help explain why pounds come back when GLP-1 medications stop. The work appeared in Cell Reports and was announced September 10, 2026 by the Harrington Discovery Institute at University Hospitals in Cleveland ^[1].

The researchers, led by Atul Chopra, MD, PhD, wanted to know what drives the hormone asprosin higher in obesity. They found an inflammatory signal, TGF-β1, doing that job. A short exposure to it left fat cells changed for weeks after the signal faded ^[1]. In mice that lost all their excess weight, asprosin and appetite stayed high, the release says ^[1]. Chopra compared it to a light switch that remains on after the finger is removed ^[1]. The team calls the lingering state "obesity memory."

Blocking the asprosin pathway changed what happened next in the animals. Interfering anywhere along the chain — the gene that produces the hormone, or the brain receptor that responds to it — prevented weight regain after dieting, and also prevented obesity risk from being inherited, according to the release ^[1]. Asprosin can cross the placenta, so the signal reaches the fetus before birth; the authors describe the result as a newborn with a programmed susceptibility to obesity ^[1].

The central persistence finding held up in a second laboratory. Seth J. Field, MD, PhD, whose lab reproduced it, is director of physician-scientist programs and chief scientific officer at Harrington Discovery Institute at UH and a professor at Case Western Reserve School of Medicine ^[1]. Analyses of existing mouse and human datasets pointed the same way, the release states, though it says human research is still needed ^[1].

Chopra's team connects the mechanism to GLP-1 medicines, which lower appetite only while they are taken. "This gives us a molecular explanation for why GLP-1 drugs, which suppress appetite while you take them, cannot fix the underlying biological memory that drives hunger back up once treatment ends," he said ^[1]. The announcement names no specific product, does not say how much weight the animals regained, and reports no measurements from people.

Why it matters for patients

Nothing about treatment changes based on this study. It involved mice, and the release says more human work is needed ^[1]. No asprosin-blocking medicine is described as available, and none is described as being tested in people.

What the finding offers is a proposed reason weight returns after a GLP-1 prescription stops — a pattern patients and prescribers already face. Chopra said the takeaway for clinicians is that relapse is not a matter of willpower or discipline, but of a lasting change in fat tissue that keeps hunger high after the weight is gone ^[1]. "We need to treat obesity as a condition that leaves lasting biological scars, not just a temporary state of excess weight," he said ^[1].

The study also raises the idea that risk may be set before birth, through a signal that passes from mother to fetus. In mice, blocking that pathway prevented the inherited risk ^[1]. Whether the same holds in people has not been established.

What happens next

Chopra said the next step is translating the work to humans: confirming that the same epigenetic memory operates in human fat tissue after weight loss, and testing whether blocking asprosin or resetting those epigenetic marks can prevent regain in people ^[1]. He said the team is interested in whether asprosin-blocking therapies could be used alongside or after GLP-1 treatment to prevent rebound ^[1]. No timeline, human study start date or drug candidate has been disclosed ^[1].